MENU
+Compare
IHE
ETF ticker: NYSE ARCA
AS OF
Jun 13 closing price
Price
$67.50
Change
-$0.37 (-0.55%)
Net Assets
577.23M

IHE stock forecast, quote, news & analysis

The investment seeks to track the investment results of the Dow Jones U... Show more

Category: #Health
IHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IHE with price predictions
Jun 13, 2025

Momentum Indicator for IHE turns positive, indicating new upward trend

IHE saw its Momentum Indicator move above the 0 level on May 28, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for IHE just turned positive on May 27, 2025. Looking at past instances where IHE's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

IHE moved above its 50-day moving average on June 02, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IHE crossed bullishly above the 50-day moving average on June 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 256 cases where IHE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for IHE moved out of overbought territory on June 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IHE broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares US Pharmaceuticals ETF ETF is 45.07B. The market cap for tickers in the group ranges from 84.71M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is PLRX at 84.71M.

High and low price notable news

The average weekly price growth across all stocks in the iShares US Pharmaceuticals ETF ETF was 2%. For the same ETF, the average monthly price growth was 9%, and the average quarterly price growth was 2%. PHAT experienced the highest price growth at 19%, while NUVB experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the iShares US Pharmaceuticals ETF ETF was -18%. For the same stocks of the ETF, the average monthly volume growth was -28% and the average quarterly volume growth was 30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 74
Price Growth Rating: 54
SMR Rating: 75
Profit Risk Rating: 79
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
IHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com